LCAT and Familial LCAT deficiency: Recently, a Phase I clinical trial [23] has shown that recombinant LCAT is safe in patients with stable cardiovascular disease and moreover, the lipid and lipoprotein abnormalities of one patient with FLD was reported to be corrected by treatment with recombinant LCAT [24].